Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004061 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00004061: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004061 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004061, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation. PURPOSE: Randomized phase II trial to study the effectiveness of biological therapy to reduce side effects in patients who are undergoing radiation therapy, chemotherapy, and peripheral stem cell transplantation in treating lymphoma or leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- BIOLOGICAL palifermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 1999-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004061
The ClinicalTrials.gov registry entry for NCT00004061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00004061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004061 about?
NCT00004061 is a clinical study titled "Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer". RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation. PURPOSE: Randomized phase II trial to study the effectiveness of biologic...
What is the current status of trial NCT00004061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 1999-05. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00004061?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), palifermin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004061?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.